ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 587

Increased Prevalence of Cardiac Disorders in Dutch Ankylosing Spondylitis Patients: The CARDAS Study

Milad Baniaamam1, Sjoerd Heslinga 2, Thelma Konings 3, Otto Kamp 3, Vokko van Halm 3, Irene van der Horst-Bruinsma 2 and Mike Nurmohamed 4, 1Amsterdam Rheumatology and immunology Center, Rheumatology, Reade, Amsterdam|Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, 3Amsterdam University Medical Center, location VUmc, Department of Cardiology, Amsterdam, Amsterdam, Netherlands, 4Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Heart disease, prevalence and inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The overall mortality rate in ankylosing spondylitis (AS) patients is increased by 60–90% compared with the general population. This higher mortality rate is predominately caused by cardiovascular disease (CVD) comprising both by increased prevalence of cardiac diseases such as valvular heart disease, conduction disturbances and cardiomyopathies as well as atherosclerotic diseases such as myocardial infarctions. However, there is some diversity in the literature and there is a lack of contemporary studies. Therefore, we investigated current prevalences of cardiac disorders in a well characterized cohorts of Dutch patients with AS.

The CARDAS study aims to describe the prevalence of CVD in AS patients in a Dutch cohort.

Methods: We performed a cross-sectional study in consecutive AS patients between 50-75 years. Subjects were recruited from a large rheumatology outpatient clinic (Reade) in Amsterdam, the Netherlands. Patients underwent echocardiography with 2D, spectral and Color Doppler imaging. Diastolic dysfunction was evaluated by an experienced cardiologist based on the AEA/ASE guideline 2009. Furthermore, an ECG, blood sample, surveys and physical examination were performed. Disease activity and function were measured with the BASFI, BASDAI and the ASDAS-CRP.

Results: 191 Consecutive AS patients were included with a median age of 58 years (54-65) of which mostly men (136/191, 71%) (Table 1). The mean disease duration was 34.9 years (± 11.9) The disease activity measures , BASDAI, ASDAS-CRP and BASFI, indicated moderate disease activity and were, respectively 3.1 (±2,3), 2.1 (±1.0) and 3.5 (1.6-5.7). The use of bDMARD’s (anti-TNF) was present in 42% of the AS patients. As cardiac manifestations are age related, AS patients were divided in 3 age categories, respectively, 50-59 years, 60-69 years and 70-75 years. Hypertension was diagnosed in respectively 45.3%, 64.1% and 85.7%. History of CVD described as angina pectoris, myocardial infarction, stroke and/or peripheral ischemia were present in respectively 7.5%, 9.4% and 19%. Diastolic dysfunction was present in respectively 40.4%, 61.9% and 89.5% of the AS patients. The diastolic dysfunction present in this population was mainly mild with 60.2% of patients presenting with grade 1 and 39.8% with grade 2 diastolic dysfunction. Moderate to severe aortic regurgitation was present in, respectively 10.4%, 12.5% and 33.4% and moderate to severe mitral valve regurgitation in 33%, 31.3% and 42.9% of the AS patients. These prevalences are substantially increased in comparison to the general Dutch population.

Conclusion: We demonstrated increased prevalences of diastolic dysfunction, aortic valve regurgitation, mitral valve regurgitation and hypertension in Dutch AS patients compared to age matched general population. Although our results suggest mandatory echocardiography screening, this first needs to be established in prospective follow-up studies.


Disclosure: M. Baniaamam, None; S. Heslinga, None; T. Konings, None; O. Kamp, None; V. van Halm, None; I. van der Horst-Bruinsma, None; M. Nurmohamed, AbbVie, 2, 8, BMS, 2, 8, Celgene, 2, 8, Eli Lilly, 2, 8, Janssen, 2, 8, Merck, 2, 8, Pfizer, 2, 8, Roche, 2, 8, UCB, 2, 8.

To cite this abstract in AMA style:

Baniaamam M, Heslinga S, Konings T, Kamp O, van Halm V, van der Horst-Bruinsma I, Nurmohamed M. Increased Prevalence of Cardiac Disorders in Dutch Ankylosing Spondylitis Patients: The CARDAS Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/increased-prevalence-of-cardiac-disorders-in-dutch-ankylosing-spondylitis-patients-the-cardas-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-prevalence-of-cardiac-disorders-in-dutch-ankylosing-spondylitis-patients-the-cardas-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology